Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRIW) Accumulated Expenses (2022 - 2025)

Historic Accumulated Expenses for Biofrontera (BFRIW) over the last 4 years, with Q3 2025 value amounting to $3.0 million.

  • Biofrontera's Accumulated Expenses changed N/A to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year change of. This contributed to the annual value of $2.4 million for FY2024, which is N/A changed from last year.
  • Biofrontera's Accumulated Expenses amounted to $3.0 million in Q3 2025.
  • Over the past 5 years, Biofrontera's Accumulated Expenses peaked at $5.6 million during Q1 2022, and registered a low of $2.4 million during Q2 2025.
  • For the 4-year period, Biofrontera's Accumulated Expenses averaged around $3.6 million, with its median value being $2.5 million (2022).
  • Examining YoY changes over the last 5 years, Biofrontera's Accumulated Expenses showed a top increase of 5535.71% in 2023 and a maximum decrease of 5535.71% in 2023.
  • Biofrontera's Accumulated Expenses (Quarter) stood at $2.5 million in 2022, then changed by 0.0% to $2.5 million in 2023, then fell by 2.88% to $2.4 million in 2024, then grew by 22.49% to $3.0 million in 2025.
  • Its Accumulated Expenses stands at $3.0 million for Q3 2025, versus $2.4 million for Q2 2025 and $2.5 million for Q1 2025.